Publications Search - Abstract View
||Serum transforming growth factor-Î²1 and risk of pancreatic cancer in three prospective cohort studies.
||Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, MÃ¤nnistÃ¶ S, Pollak M, Stolzenberg-Solomon RZ
||Cancer Causes Control
||2014 Jun 10
||IIB, NEB, OEEB
||PURPOSE: Clinically evident chronic pancreatitis is a strong risk factor for pancreatic cancer. A small Japanese cohort study previously reported that pre-diagnostic serum transforming growth factor-Î²1 (TGF-Î²1) concentration, a potential marker of subclinical pancreatic inflammation, was associated with higher risk of pancreatic cancer. We further explored this association in a larger prospective study. METHODS: Serum TGF-Î²1 concentrations were measured in pre-diagnostic samples from 729 pancreatic cancer cases and 907 matched controls from a cohort of Finnish male smokers (the Alpa-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study) and two cohorts of US men and women, the Cancer Prevention Study-II and the Prostate Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Multivariable-adjusted odds ratios (ORs) were estimated using conditional logistic regression. RESULTS: Overall, serum TGF-Î²1 concentration was not associated with a clear increase in pancreatic cancer risk (OR 1.36, 95Â % confidence interval (CI) 0.98-1.88 for highest vs. lowest quintile, p trendÂ =Â 0.20). However, this association differed significantly by follow-up time (pÂ =Â 0.02). Serum TGF-Î²1 concentration was not associated with risk during the first 10Â years of follow-up, but was associated with higher risk during follow-up after 10Â years (OR 2.13, 95Â % CI 1.23-3.68 for highest vs. lowest quintile, p trendÂ =Â 0.001). During follow-up after 10Â years, serum TGF-Î²1 was associated with higher risk only in the ATBC cohort, although most subjects were from ATBC during this time period and statistical evidence for heterogeneity across cohorts was limited (pÂ =Â 0.14). CONCLUSIONS: These results suggest that high serum TGF-Î²1 may be associated with increased risk of pancreatic cancer although a long follow-up period may be needed to observe this association.